Drug
Sacituzumab Govitecan Hziy
Sacituzumab Govitecan Hziy: highest development phase Phase 3, developed by Gilead Sciences. 4 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Gilead Sciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| Sacituzumab govitecan-hziy (SG) NCT05633654 | Phase 3 | Triple Negative Breast Cancer |
| Sacituzumab govitecan-hziy NCT06486441 | Phase 3 | Endometrial Cancer |
| Sacituzumab Govitecan-hziy NCT03901339 | Phase 3 | Metastatic Breast Cancer |
| Sacituzumab Govitecan-hziy NCT05101096 | Phase 1/2 | Advanced Solid Tumor |
Latest
No recent events.
Follow Sacituzumab Govitecan Hziy on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.